Hematology
Conference Coverage
Repeat VTE risk heightened in HIV patients
SEATTLE – Two studies detail the risk factors of first-time venous thromboembolism and heightened incidence of repeat VTE in patients with HIV.
Conference Coverage
Gene therapy in hemophilia is just version 1.0
PRAGUE – The biggest question for gene therapy today is durability, according to Dr. John Pasi.
Conference Coverage
Myeloma therapies raise cardiovascular risks
WASHINGTON – The proteasome inhibitor carfilzomib increases risk for heart failure, and thalidomide analogs increase the risk for venous...
Conference Coverage
Think duration, not dose, when managing bleeding with non–factor replacements
PRAGUE – The duration of treatment is more strongly linked to thromboembolism than dose magnitude, according to Dr. Andreas Tiede.
News from the FDA/CDC
FDA: Safety signal emerged with higher dose of tofacitinib in RA study
The FDA is working with Pfizer to better understand how the signal affects patients and how the drug should be used, the agency said in a...
News
ICYMI: Rivaroxaban reduces VTE incidence in ambulatory cancer patients
However, the reduction lost significance if treatment with rivaroxaban was halted.
News
Supplementary compression doesn’t improve DVT odds in critically ill
SAN DIEGO – The procedure carries few risks, aside from patient discomfort.
News
FDA approves caplacizumab for aTTP
The injection is approved in combination with plasma exchange and immunosuppressive therapy for adults with acquired thrombotic thrombocytopenia...
Conference Coverage
Biomarkers predict VTE risk with menopausal oral hormone therapy
CHICAGO – Pretreatment high D-dimer spells 500% increased VTE risk on oral hormone therapy.
News
Meta-analysis: IVIG bests anti-D on platelet count in pediatric ITP
But the clinical significance of this finding is unclear because of the lack of data on bleeding symptoms, according to authors of the meta-...